Blue Note Therapeutics is a prescription digital therapeutics company singularly dedicated to helping patients live better. Blue Note is merging deep scientific and clinical expertise with digital and gaming ideas to transform care for seriously ill patients. Working closely with leading medical researchers and patient advocacy organizations, Blue Note is creating clinically validated, FDA-approvable, and prescription-only digital devices to treat the burden of illness. The company was founded in 2018 and is based in San Francisco, California.

Moovcare® is a medical application that needs to be prescribed by your oncologist and helps you stay connected to your medical team. If your physician determines that you are eligible to be included into Moovcare® platform, you will start receiving a digital questionnaire once a week, which you can answer via your smartphone, laptop or tablet.

You will be required to self report your symptoms, Moovcare® algorithm will analyse your answers and if it detects an anomaly or complication, an immediate notification will be sent to your treating physician. Moovcare is a digital therapeutic that uses a simple questionnaire to detect relapse or complications during follow-up of lung cancer patients. It enables monitoring patient symptoms on a weekly basis and alerting medical teams to the first signs of an anomaly. It was founded in 2014 and is based in Jerusalem, Israel.

We are a multidisciplinary team of clinicians, technologists, and behavioral experts united to tackle some of the most significant challenges in healthcare.

Drawing on multi-year clinical studies conducted by leading oncologists in the US and France, we have developed the first digital platform for the early detection of diseases. These studies highlight the impact of patient-reported symptoms on survival and quality of life, forming the foundation of our innovative approach.

Cancer-related distress, which can be defined as any unpleasant feeling, emotion, or experience that affects a cancer patient’s quality of life or ability to cope with cancer diagnosis and treatment, affects millions of people. Fewer than half of those who experience cancer-related distress have access to the mental health care they need to find relief. Blue Note Therapeutics is working to close this gap.

Moovcare® was proven in a clinical study to significantly improve lung cancer patients’ well being, as well as the communication with the medical team.